

## Justification for the selection of a substance for CoRAP inclusion

- Update -

<b>Substance Name (Public Name):</b>	3-Methylpyrazole
<b>Chemical Group:</b>	Pyrazole
<b>EC Number:</b>	215-925-7
<b>CAS Number:</b>	1453-58-3
<b>Submitted by:</b>	BE CA
<b>Date:</b>	17/03/2015 21/03/2017 (Updated version)

### Note

This document has been prepared by the evaluating Member State given in the CoRAP update.

## Contents

1	IDENTITY OF THE SUBSTANCE.....	3
1.1	Other identifiers of the substance	3
2	CLASSIFICATION AND LABELLING.....	4
2.1	Harmonised Classification in Annex VI of the CLP	4
2.2	Self classification	4
2.3	Proposal for Harmonised Classification in Annex VI of the CLP	4
3	INFORMATION ON AGGREGATED TONNAGE AND USES .....	4
4	OTHER COMPLETED/ONGOING REGULATORY PROCESSES THAT MAY AFFECT SUITABILITY FOR SUBSTANCE EVALUATION.....	5
5	JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE CoRAP SUBSTANCE ....	5
5.1	Legal basis for the proposal	5
5.2	Selection criteria met (why the substance qualifies for being in CoRAP)	5
5.3	Initial grounds for concern to be clarified under Substance Evaluation	6
5.4	Preliminary indication of information that may need to be requested to clarify the concern	7
5.5	Potential follow-up and link to risk management	7

## 1 IDENTITY OF THE SUBSTANCE

### 1.1 Other identifiers of the substance

Table 1: Substance identity

<b>EC name:</b>	3-methylpyrazole
<b>IUPAC name:</b>	3-methyl-1H-pyrazole
<b>Index number in Annex VI of the CLP Regulation</b>	NA
<b>Molecular formula:</b>	C <sub>4</sub> H <sub>6</sub> N <sub>2</sub>
<b>Molecular weight or molecular weight range:</b>	82.10 g/mol
<b>Synonyms/Trade names:</b>	/


**Type of substance**

Mono-constituent

Multi-constituent

UVCB

**Structural formula:**



### 1.2 Similar substances/grouping possibilities

Not known

## 2 CLASSIFICATION AND LABELLING

### 2.1 Harmonised Classification in Annex VI of the CLP

NA

### 2.2 Self classification

- In the registration

Acute Tox. 4 H302: Harmful if swallowed.

Skin Corr. 1B H314: Causes severe skin burns and eye damage.

Eye Damage 1 H318: Causes serious eye damage

Repr. 2; H361: Suspected of damaging fertility or the unborn child <state specific effect if known> <state route of exposure if it is conclusively proven that no other routes of exposure cause the hazard>.

route of exposure: Oral

- The following hazard classes are in addition notified among the aggregated

Skin Irrit. 2; H315: Causes skin irritation

Eye Irrit. 2; H319: Causes serious eye irritation

STOT SE 3; H335 (Respiratory sys...)(Inhalation): May cause respiratory irritation

Acute Tox. 3; H331: Toxic if inhaled

STOT RE 2; H373(all organs): May cause damage to organs through prolonged or repeated exposure

### 2.3 Proposal for Harmonised Classification in Annex VI of the CLP

NA

## 3 INFORMATION ON AGGREGATED TONNAGE AND USES

From ECHA dissemination site*			
<input checked="" type="checkbox"/> 1 - 10 tpa	<input type="checkbox"/> 10 - 100 tpa	<input type="checkbox"/> 100 - 1000 tpa	
<input type="checkbox"/> 1000 - 10,000 tpa	<input type="checkbox"/> 10,000 - 100,000 tpa	<input type="checkbox"/> 100,000 - 1,000,000 tpa	
<input type="checkbox"/> 1,000,000 - 10,000,000 tpa	<input type="checkbox"/> 10,000,000 - 100,000,000 tpa	<input type="checkbox"/> > 100,000,000 tpa	
<input type="checkbox"/> <1 . . . . . >+ tpa (e.g. 10+ ; 100+ ; 10,000+ tpa)		<input type="checkbox"/> Confidential	
*the total tonnage band has been calculated by excluding the intermediate uses; for details see the Manual for Dissemination and Confidentiality under REACH Regulation (section 2.6.11): <a href="https://echa.europa.eu/documents/10162/22308542/manual_dissemination_en.pdf/7e0b87c2-2681-4380-8389-cd655569d9f0">https://echa.europa.eu/documents/10162/22308542/manual_dissemination_en.pdf/7e0b87c2-2681-4380-8389-cd655569d9f0</a>			
<input type="checkbox"/> Industrial use	<input checked="" type="checkbox"/> Professional use	<input type="checkbox"/> Consumer use	<input type="checkbox"/> Closed System
Formulation Handling of nitrification inhibitors and liquid fertilisers with nitrification inhibitors by retailers. Handling and application of liquid fertilisers by farmers.			

#### 4 OTHER COMPLETED/ONGOING REGULATORY PROCESSES THAT MAY AFFECT SUITABILITY FOR SUBSTANCE EVALUATION

<input type="checkbox"/> Compliance check, Final decision	<input type="checkbox"/> Dangerous substances Directive 67/548/EEC
<input type="checkbox"/> Testing proposal	<input type="checkbox"/> Existing Substances Regulation 793/93/EEC
<input type="checkbox"/> Annex VI (CLP)	<input type="checkbox"/> Plant Protection Products Regulation 91/414/EEC
<input type="checkbox"/> Annex XV (SVHC)	<input type="checkbox"/> Biocidal Products Directive 98/8/EEC ; Biocidal Product Regulation (Regulation (EU) 528/2012)
<input type="checkbox"/> Annex XIV (Authorisation)	<input type="checkbox"/> Other (provide further details below)
<input type="checkbox"/> Annex XVII (Restriction)	
Information on other completed/ongoing regulatory processes was not found.	

#### 5 JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE CoRAP SUBSTANCE

##### 5.1 Legal basis for the proposal

- Article 44(2) (refined prioritisation criteria for substance evaluation)
- Article 45(5) (Member State priority)

##### 5.2 Selection criteria met (why the substance qualifies for being in CoRAP)

- Fulfils criteria as CMR/ Suspected CMR
- Fulfils criteria as Sensitiser/ Suspected sensitiser
- Fulfils criteria as potential endocrine disrupter
- Fulfils criteria as PBT/vPvB / Suspected PBT/vPvB
- Fulfils criteria high (aggregated) tonnage (*tpa* > 1000)
- Fulfils exposure criteria
- Fulfils MS's (national) priorities

### 5.3 Initial grounds for concern to be clarified under Substance Evaluation

<b>Hazard based concerns</b>		
CMR <input type="checkbox"/> C <input type="checkbox"/> M <input checked="" type="checkbox"/> R	Suspected CMR <sup>1</sup> <input type="checkbox"/> C <input type="checkbox"/> M <input checked="" type="checkbox"/> R	<input checked="" type="checkbox"/> Potential endocrine disruptor
<input type="checkbox"/> Sensitiser	<input type="checkbox"/> Suspected Sensitiser <sup>1</sup>	
<input type="checkbox"/> PBT/vPvB	<input type="checkbox"/> Suspected PBT/vPvB <sup>1</sup>	<input type="checkbox"/> Other (please specify below)
<b>Exposure/risk based concerns</b>		
<input checked="" type="checkbox"/> Wide dispersive use	<input type="checkbox"/> Consumer use	<input type="checkbox"/> Exposure of sensitive populations
<input checked="" type="checkbox"/> Exposure of environment	<input type="checkbox"/> Exposure of workers	<input type="checkbox"/> Cumulative exposure
<input type="checkbox"/> High RCR	<input type="checkbox"/> High (aggregated) tonnage	<input type="checkbox"/> Other (please specify below)
<p><b>Reprotoxicity:</b> self-classification in the registration dossier Repro 2 (but 31 notified C&amp;L do not contain this classification)</p> <p>There is a need for an assessment of the observed effects on offsprings in relation to the toxic effect of the substance on the maternal organisms.</p> <p>If the effects on fetuses are not considered to be related to the observed maternal toxicity, the classification could be more severe.</p> <p>Dose related reprotoxic effects are seen in an OECD Guideline 414 (Prenatal Developmental Toxicity Study). The test substance was administered to the animals orally (by gavage; 15, 45 and 90 mg/kg body weight) once a day during the period of major organogenesis (day 6 to day 15 p.c.).</p> <p><u>Embryotoxic / teratogenic effects are:</u></p> <p>At dose group 90 mg/kg, embryo-/foetotoxicity and clear indication for teratogenicity: Besides reduced fetal body weights and delayed ossification, malformations of the urogenital tract, cardiovascular system, thoracic vertebral bodies were observed</p> <p>At dose group 45 mg/kg, embryo-/foetotoxicity, but no teratogenic effects</p> <p>At 15 mg/kg bw/day, no signs of developmental toxicity.</p> <p><u>Maternal toxic effects are reported (details are not given)</u></p> <p>At dose group: 90 mg/kg -reduced food consumption -significantly lower body weights</p> <p>At dose group: 45 mg/kg -reduced food consumption</p> <p>Furthermore, there are indications that 3-methylpyrazole crosses the placental barrier.</p> <p><b>Potential endocrine disruptor</b> : concern linked to the group family (pyrazole)</p>		

<sup>1</sup> CMR/Sensitiser: known carcinogenic and/or mutagenic and/or reprotoxic properties/known sensitising properties (according to CLP harmonized or registrant self-classification or CLP Inventory)

Suspected CMR/Suspected sensitiser: suspected carcinogenic and/or mutagenic and/or reprotoxic properties/suspected sensitising properties (not classified according to CLP harmonized or registrant self-classification)

Suspected PBT: Potentially Persistent, Bioaccumulative and Toxic

**Exposure:**

The registrant did not take into account the application of the fertilizer on crops and this is most likely the path with the highest environmental exposure. In view of the tonnage of the imported substance and the foreseen use, wide dispersive use is expected.

**5.4 Preliminary indication of information that may need to be requested to clarify the concern**

<input checked="" type="checkbox"/> Information on toxicological properties	<input type="checkbox"/> Information on physico-chemical properties
<input type="checkbox"/> Information on fate and behaviour	<input checked="" type="checkbox"/> Information on exposure
<input type="checkbox"/> Information on ecotoxicological properties	<input type="checkbox"/> Information on uses
<input checked="" type="checkbox"/> Information ED potential	<input type="checkbox"/> Other (provide further details below)

An extended-one generation test could be requested to clarify the concern.

**5.5 Potential follow-up and link to risk management**

<input checked="" type="checkbox"/> Harmonised C&L	<input type="checkbox"/> Restriction	<input checked="" type="checkbox"/> Authorisation	<input type="checkbox"/> Other (provide further details)
----------------------------------------------------	--------------------------------------	---------------------------------------------------	----------------------------------------------------------

Depending on the outcome of the evaluation any of the above mentioned risk management measures could be initiated if warranted.